Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextromethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 7/20 | 0.95 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.95 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.95 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.95 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.95 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.95 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.95 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomethorphan SCHEMBL4910539 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL4894005 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL121923 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL1321395 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4532860 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL30052214 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4882307 | 0.99 | CYP2D6 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL121924 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL3325972 | 0.99 | GRIN1 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL6855351 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230158160-A1 | PHARMACEUTICAL COMPOSITION OF EXTENDED-RELEASE ORAL SUSPENSION AND PROCESS FOR PREPARATION THEREOF | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2023-05-25 | — | — | US | claimed |
| EP-4153146-A1 | PHARMACEUTICAL COMPOSITION OF EXTENDED-RELEASE ORAL SUSPENSION AND PROCESS FOR PREPARATION THEREOF | Lyrus Life Sciences Pvt. LTD. (IN) | 2023-03-29 | — | — | EP | claimed |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12508315-B2 | Use of vitamin E TPGS as a taste masking agent for bitter drugs | HYLORIS DEVELOPMENTS SA (BE) | 2025-12-30 | — | — | US | disclosed |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345436-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | HYLORIS DEV SA (BE) | 2025-11-13 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2022109050-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-111807968-B | Synthetic method of 2- (1-cyclohexenyl) ethylamine | 复旦大学 | 2022-05-20 | — | — | CN | disclosed |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2022-05-19 | — | — | US | disclosed |
| CN-114340608-A | Pharmaceutical composition and application thereof | 深圳信立泰药业股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220071989-A1 | METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTERATED DEXTROMETHORPHAN AND QUINIDINE | AVANIR PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11234897-B2 | Packaged multi-dose liquid dextromethorphan hydrobromide formulation | DXM Pharmaceutical, Inc. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2022018630-A1 | NOVEL PROCESSES FOR THE PREPARATION OF RAPID MELT GRANULES | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017300-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-27 | — | — | WO | disclosed |
| EP-3941469-A1 | METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTERATED DEXTROMETHORPHAN AND QUINIDINE | Avanir Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345436-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | TAS2R5, TAS2R10, TAS2R50 | GRIN2A 169/4885SIGMAR1 237/4885CYP2D6 81/4885 |
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A4, SLC6A3, SIGMAR1 | GRIN2A 887/4885SIGMAR1 3/4885CYP2D6 25/4885 |
| US-20220071989-A1 | METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTERATED DEXTROMETHORPHAN AND QUINIDINE | DRD2, OPRD1, QDPR | GRIN2A 101/4885SIGMAR1 14/4885CYP2D6 10/4885 |
| US-12508315-B2 | Use of vitamin E TPGS as a taste masking agent for bitter drugs | SLC6A4, SLC6A3, CHRM5 | GRIN2A 510/4885SIGMAR1 183/4885CYP2D6 125/4885 |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A3, SIGMAR1, SLC6A4 | GRIN2A 741/4885SIGMAR1 2/4885CYP2D6 29/4885 |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | GRIN2A 1325/4885SIGMAR1 2238/4885CYP2D6 1358/4885 |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | GRIN2A 1325/4885SIGMAR1 2238/4885CYP2D6 1358/4885 |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SIGMAR1, OPRK1, SLC6A2 | GRIN2A 597/4885SIGMAR1 1/4885CYP2D6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.